• About
  • Partnerships
  • Challenges
  • Awards
  • Grant Opportunities
  • News

Novel Therapy Targeting the Cryptosporidium Virus

Nigel Yarlett of Pace University in the U.S. will determine whether a virus that infects the intestinal parasite Cryptosporidium is a valuable target for developing drugs against the associated chronic diarrheal disease, which causes substantial morbidity and mortality in young children in low-resource settings. The double-stranded RNA Cryspoviruses are not harmful to the parasite, and instead likely enhance the parasite's ability to infect and harm humans. They will create a continuous in vitro culture of the Cryptosporidium parasite carrying viruses that will be genetically modified to fluoresce for easy monitoring, and also use RNA interference to generate a parasite strain that does not contain any viruses. These tools will be used to study the role of the virus in the growth and development of the parasite. Ultimately, a drug targeting the virus, rather than the parasite itself, may be less toxic to the good bacteria in the human gut, and less likely to drive the development of drug resistance.

More information about Accelerate Development of New Therapies for Childhood Cryptosporidium Infection (Round 18)

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit www.grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.